Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.71 - $17.11 $521,577 - $833,257
-48,700 Reduced 70.07%
20,800 $262,000
Q2 2024

Aug 14, 2024

BUY
$3.89 - $20.97 $254,017 - $1.37 Million
65,300 Added 1554.76%
69,500 $879,000
Q1 2024

May 15, 2024

BUY
$3.76 - $6.02 $15,792 - $25,284
4,200 New
4,200 $20,000
Q2 2023

Aug 14, 2023

SELL
$6.67 - $9.52 $94,047 - $134,232
-14,100 Reduced 59.75%
9,500 $70,000
Q1 2023

May 15, 2023

BUY
$5.76 - $12.48 $12,672 - $27,456
2,200 Added 10.28%
23,600 $163,000
Q4 2022

Feb 14, 2023

SELL
$8.86 - $25.04 $44,300 - $125,200
-5,000 Reduced 18.94%
21,400 $219,000
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $480,480 - $2.01 Million
26,400 New
26,400 $480,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $680M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.